StockData
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD) stock

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.01−0.60 (-16.62%)

Close on Nov 17, 2026Market cap $321.08MP/E –Yield –

Relmada Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Relmada Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$65.13M. For fiscal 2025 it was -$59.10M. The highest annual figure on record is -$3.16M in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$59.10M–
FY2024Dec 31, 2024-$83.89M–
FY2023Dec 31, 2023-$103.70M–
FY2022Dec 31, 2022-$161.25M–
FY2021Dec 31, 2021-$125.70M–
FY2019Jun 30, 2019-$12.73M–
FY2018Jun 30, 2018-$6.92M–
FY2017Jun 30, 2017-$7.22M–
FY2016Jun 30, 2016-$16.22M–
FY2013Dec 31, 2013-$6.77M–
FY2012Dec 31, 2012-$3.16M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$15.01M–
Q1 FY2026CQ1 2026Mar 31, 2026-$19.46M–
Q4 FY2025CQ4 2025Dec 31, 2025-$20.33M–
Q3 FY2025CQ3 2025Sep 30, 2025-$10.33M–
Q2 FY2025CQ2 2025Jun 30, 2025-$10.22M–
Q1 FY2025CQ1 2025Mar 31, 2025-$18.22M–
Q4 FY2024CQ4 2024Dec 31, 2024-$19.08M–
Q3 FY2024CQ3 2024Sep 30, 2024-$23.01M–
Q2 FY2024CQ2 2024Jun 30, 2024-$18.82M–
Q1 FY2024CQ1 2024Mar 31, 2024-$22.99M–
Q4 FY2023CQ4 2023Dec 31, 2023-$26.83M–
Q3 FY2023CQ3 2023Sep 30, 2023-$22.69M–
Q2 FY2023CQ2 2023Jun 30, 2023-$26.03M–
Q1 FY2023CQ1 2023Mar 31, 2023-$28.15M–
Q4 FY2022CQ4 2022Dec 31, 2022-$38.70M–
Q1 FY2022CQ1 2022Mar 31, 2022-$38.30M–
Q4 FY2021CQ4 2021Dec 31, 2021-$34.18M–
Q3 FY2021CQ3 2021Sep 30, 2021-$42.65M–
Q2 FY2021CQ2 2021Jun 30, 2021-$26.46M–
Q1 FY2021CQ1 2021Mar 31, 2021-$22.41M–
Q4 FY2019CQ2 2019Jun 30, 2019-$4.14M–
Q3 FY2019CQ1 2019Mar 31, 2019-$2.70M–
Q2 FY2019CQ4 2018Dec 31, 2018-$3.48M–
Q1 FY2019CQ3 2018Sep 30, 2018-$2.41M–
Q4 FY2018CQ2 2018Jun 30, 2018-$1.93M–
Q3 FY2018CQ1 2018Mar 31, 2018-$2.55M–
Q2 FY2018CQ4 2017Dec 31, 2017-$1.46M–
Q1 FY2018CQ3 2017Sep 30, 2017-$980.86K–
Q4 FY2017CQ2 2017Jun 30, 2017-$1.78M–
Q3 FY2017CQ1 2017Mar 31, 2017-$2.28M–
Q2 FY2017CQ4 2016Dec 31, 2016-$1.54M–
Q1 FY2017CQ3 2016Sep 30, 2016-$1.62M–
Q4 FY2016CQ2 2016Jun 30, 2016-$3.10M–
Q3 FY2016CQ1 2016Mar 31, 2016-$2.75M–
Q2 FY2016CQ4 2015Dec 31, 2015-$5.72M–
Q1 FY2016CQ3 2015Sep 30, 2015-$4.63M–
Q4 FY2013CQ4 2013Dec 31, 2013-$5.06M–
Q3 FY2013CQ3 2013Sep 30, 2013-$481.84K–

More Relmada Therapeutics figures

See a number that looks wrong?